Important COVID-19 information: All event teams are taking action to ensure health and safety of all delegates. This will result in postponement, change to online event or other changes. Please visit the event pages to get the latest information. If you follow the event you will be updated on the latest changes. Please stay safe in these difficult times.

Past event: Pain Management Summit

Impact of this Evolving Industry through the development, understanding, and impact of Abuse Resistant Technologies, Cannabinoids, & Other Novel Alternatives in Pain Management

The need for powerful pain medication remains crucial for countless different types of pain conditions. Novel innovations, including abuse-resistant technologies, non-opioid pain drugs, cannabinoid therapeutics, and others in the early stages are making breakthroughs in the pain industry.

While regulations continue to tighten the potential for new drug approvals, it is essential to be aware of all changes in the industry. The Pain Management Summit provides an in-depth evaluation of the current trends in pain therapeutics and technologies, insight on the use of data analytics in prevention and treatment of pain, and an analysis of the future of the pain space.

Top Five Reasons to Attend:

  1. Learn about current novel pain drug candidates and the top trends in pain research and drug formulation, including abuse-resistant technology
  2. Become updated on the newest pain management practices/methods
  3. Gauge the most recent FDA regulations and initiatives regarding opioids
  4. Discover how strategic partnerships and drug repurposing can increase the efficiency of the pain drug development process
  5. Explore how data analytics can improve all levels of the distribution channel, including market access

Attendee Benefits

  • Network and learn with pain management professionals, pharmaceutical developers, healthcare providers, and other stakeholders
  • Hear about the most novel analgesics in development
  • Understand how abuse-resistant technologies are evolving beyond opioids and being used for stimulants and other new chemical entities
  • Understand how Cannabinoids are improving the quality of pain treatment
  • Identify the issues and miscommunication between care providers and guidelines when addressing complex pain scenarios
  • Harness industry best practices to attract payers and maximize market access

Who Should Attend:

Pharma, biotech, med device, and healthcare professionals responsible for:
  • Pain / Pain Medicine / Pain Management
  • Abuse / Deterrent / Deterrence / Resistant / Resistance / Abuse deterrent / Abuse Deterrence
  • Abuse / Drug Abuse
  • Addiction / Addiction Treatment / Addiction Medicine
  • Cannabis / Cannabinoid
  • Drug Safety
  • Risk Management / REMS
  • Toxicology
  • Behavioral Psychiatry / Behavioral Health
  • Diversion
  • Formulations
  • Pharmaceutical Development
  • Preclinical Development
  • Clinical Development
  • Clinical Development / Operations / Affairs / Programs
  • Policy
  • Regulatory Affairs
  • Scientific Affairs
  • Medical Affairs
  • Legal Affairs / Legal Counsel
  • Market Access
  • Marketing
  • Pharmacology / Clinical Pharmacology / Safety Pharmacology
  • Pharmacovigilance
  • Pharmacy
  • Analytical Development
  • Anesthesiology
  • Neurobiology / Neurology
  • CNS / Neuroscience
  • Commercial Affairs
  • Managed Care
  • Palliative Care
  • Pharmacoeconomics / Health Economics / Outcomes Research / HEOR
  • Education
  • Informatics
  • Quality
  • R&D
  • Epidemiology / Pharmacoepidemiology

This event is also of interest to:
  • Abuse Liability Service Providers
  • CROs
  • Drug Abuse Registry / Surveillance Specialists
  • Formulation Service Providers
  • Law Firms
  • Pharmacokinetics Service Providers
  • Regulatory Specialists
  • REMS / Pharmacovigilance Specialists
  • Toxicology Specialists
  • University Professors Researching Pain / Addiction / Cannabinoids


  • Caroline Arout, Ph.D., Research Scientist and Assistant Professor of Clinical Neurobiology, NEW YORK STATE PSYCHIATRIC INSTITUTE AT COLUMBIA UNIVERSITY IRVING MEDICAL CENTER
  • Scott L. Dax, Ph.D., Chief Scientific Officer, CERSCI THERAPEUTICS
  • Nial DeMena, Chief Executive Officer, MANNA MOLECULAR SCIENCE
  • Ashley Elsner, J.D., MBA, Chief Executive Officer and Founder, ARTERY PAY
  • Danielle Friend, Ph.D., Director, Science and Regulatory Affairs, BIOTECHNOLOGY INNOVATION ORGANIZATION
  • Jeffrey Fudin, Pharm.D., Chief Executive Officer and Chief Medical Officer, REMITIGATE, LLC.
  • Gary W. Jay, M.D., FAAPM, Clinical Professor, Dept. of Neurology, Division: Headache/Pain at UNC, UNIVERSITY OF NORTH CAROLINA, CHAPEL HILL
  • Steven D. Passik, Ph.D., Vice President, Scientific Affairs, Education, and Policy, COLLEGIUM PHARMACEUTICALS
  • Tim Peara, President and Finance Director, BRIDGE THERAPEUTICS
  • Joseph V. Pergolizzi, M.D., Senior Partner, NAPLES ANESTHESIA AND PAIN ASSOCIATES
  • Robert Raffa, Ph.D., Chief Scientific Officer, NEUMENTUM, INC.
  • Sebastian Schwier, Ph.D., Director, Transfer and Integration Management, GRUNENTHAL
  • Joe Stauffer, Chief Medical Officer, INHERIS BIOPHARMA
  • Alex Wasyl, Chief Executive Officer, NEXIEN BIOPHARMA
  • Debra R. Wilson, Ph.D., Contributing Faculty, WALDEN UNIVERSITY & AUSTIN PEAY STATE UNIVERSITY
  • John A. Zebala M.D., Ph.D., Chief Executive Officer and President, SYNTRIX PHARMACEUTICALS

Please fill in your name and email to receive the Summit Agenda of this event.


The Inn at Penn, A Hilton Hotel
3600 Sansom Street, 19104
Philadelphia, PA, USA

To make reservations, please call (215) 823-6240 and request the negotiated rate for ExL's November Meetings. You may also make reservations online: Click Here

The group rate is available until October 28, 2019. Please book your room early as rooms available at this rate are limited.
Event details
Organizer : ExL
Event type : Conference
Reference : ASDE-21537